Cargando…

Impaired Tight Junctions in Atopic Dermatitis Skin and in a Skin-Equivalent Model Treated with Interleukin-17

Tight junction (TJ) dysfunction in the stratum granulosum leads to aberrant barrier function of the stratum corneum (SC) in the epidermis. However, it is unclear whether TJs are perturbed in atopic dermatitis (AD), a representative aberrant SC-related skin disease, and whether some factors related t...

Descripción completa

Detalles Bibliográficos
Autores principales: Yuki, Takuo, Tobiishi, Megumi, Kusaka-Kikushima, Ayumi, Ota, Yukiko, Tokura, Yoshiki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5010286/
https://www.ncbi.nlm.nih.gov/pubmed/27588419
http://dx.doi.org/10.1371/journal.pone.0161759
_version_ 1782451660972359680
author Yuki, Takuo
Tobiishi, Megumi
Kusaka-Kikushima, Ayumi
Ota, Yukiko
Tokura, Yoshiki
author_facet Yuki, Takuo
Tobiishi, Megumi
Kusaka-Kikushima, Ayumi
Ota, Yukiko
Tokura, Yoshiki
author_sort Yuki, Takuo
collection PubMed
description Tight junction (TJ) dysfunction in the stratum granulosum leads to aberrant barrier function of the stratum corneum (SC) in the epidermis. However, it is unclear whether TJs are perturbed in atopic dermatitis (AD), a representative aberrant SC-related skin disease, and whether some factors related to AD pathogenesis induce TJ dysfunction. To address these issues, we investigated the alterations of TJs in AD skin and the effects of Th2 and Th17 cytokines on TJs in a skin-equivalent model. The levels of TJ proteins were determined in the epidermis of nonlesional and lesional skin sites of AD. Western blot and immunohistochemical analyses revealed that the levels of zonula occludens 1 were decreased in the nonlesional sites of AD, and the levels of zonula occludens 1 and claudin-1 were decreased in the lesional sites relative to the levels in skin from healthy subjects. Next, we examined the effects of interleukin (IL)-4, tumor necrosis factor-α, IL-17, and IL-22 on the TJ barrier in a skin-equivalent model. Only IL-17 impaired the TJ barrier. Furthermore, we observed a defect in filaggrin monomer degradation in the IL-17–treated skin model. Thus, TJs are dysfunctional in AD, at least partly, due to the effect of IL-17, which may result in an aberrant SC barrier.
format Online
Article
Text
id pubmed-5010286
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-50102862016-09-27 Impaired Tight Junctions in Atopic Dermatitis Skin and in a Skin-Equivalent Model Treated with Interleukin-17 Yuki, Takuo Tobiishi, Megumi Kusaka-Kikushima, Ayumi Ota, Yukiko Tokura, Yoshiki PLoS One Research Article Tight junction (TJ) dysfunction in the stratum granulosum leads to aberrant barrier function of the stratum corneum (SC) in the epidermis. However, it is unclear whether TJs are perturbed in atopic dermatitis (AD), a representative aberrant SC-related skin disease, and whether some factors related to AD pathogenesis induce TJ dysfunction. To address these issues, we investigated the alterations of TJs in AD skin and the effects of Th2 and Th17 cytokines on TJs in a skin-equivalent model. The levels of TJ proteins were determined in the epidermis of nonlesional and lesional skin sites of AD. Western blot and immunohistochemical analyses revealed that the levels of zonula occludens 1 were decreased in the nonlesional sites of AD, and the levels of zonula occludens 1 and claudin-1 were decreased in the lesional sites relative to the levels in skin from healthy subjects. Next, we examined the effects of interleukin (IL)-4, tumor necrosis factor-α, IL-17, and IL-22 on the TJ barrier in a skin-equivalent model. Only IL-17 impaired the TJ barrier. Furthermore, we observed a defect in filaggrin monomer degradation in the IL-17–treated skin model. Thus, TJs are dysfunctional in AD, at least partly, due to the effect of IL-17, which may result in an aberrant SC barrier. Public Library of Science 2016-09-02 /pmc/articles/PMC5010286/ /pubmed/27588419 http://dx.doi.org/10.1371/journal.pone.0161759 Text en © 2016 Yuki et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Yuki, Takuo
Tobiishi, Megumi
Kusaka-Kikushima, Ayumi
Ota, Yukiko
Tokura, Yoshiki
Impaired Tight Junctions in Atopic Dermatitis Skin and in a Skin-Equivalent Model Treated with Interleukin-17
title Impaired Tight Junctions in Atopic Dermatitis Skin and in a Skin-Equivalent Model Treated with Interleukin-17
title_full Impaired Tight Junctions in Atopic Dermatitis Skin and in a Skin-Equivalent Model Treated with Interleukin-17
title_fullStr Impaired Tight Junctions in Atopic Dermatitis Skin and in a Skin-Equivalent Model Treated with Interleukin-17
title_full_unstemmed Impaired Tight Junctions in Atopic Dermatitis Skin and in a Skin-Equivalent Model Treated with Interleukin-17
title_short Impaired Tight Junctions in Atopic Dermatitis Skin and in a Skin-Equivalent Model Treated with Interleukin-17
title_sort impaired tight junctions in atopic dermatitis skin and in a skin-equivalent model treated with interleukin-17
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5010286/
https://www.ncbi.nlm.nih.gov/pubmed/27588419
http://dx.doi.org/10.1371/journal.pone.0161759
work_keys_str_mv AT yukitakuo impairedtightjunctionsinatopicdermatitisskinandinaskinequivalentmodeltreatedwithinterleukin17
AT tobiishimegumi impairedtightjunctionsinatopicdermatitisskinandinaskinequivalentmodeltreatedwithinterleukin17
AT kusakakikushimaayumi impairedtightjunctionsinatopicdermatitisskinandinaskinequivalentmodeltreatedwithinterleukin17
AT otayukiko impairedtightjunctionsinatopicdermatitisskinandinaskinequivalentmodeltreatedwithinterleukin17
AT tokurayoshiki impairedtightjunctionsinatopicdermatitisskinandinaskinequivalentmodeltreatedwithinterleukin17